# A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Source: https://onco.cc/trials/nct07533123/  
OnCo record `nct07533123` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JSKN016 in triple-negative breast cancer, now recruiting.

## Summary

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care. ClinicalTrials.gov record last updated 2026-04-16: recruiting. Enrollment is planned at 364 participants. Primary completion is estimated at 2029-03-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Sacituzumab Govitecan for Injection. Registered primary measures: PFS (Progression-Free Survival); OS (Overall Survival).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: ctgov-ingest
- Registry id: NCT07533123
- Phase: 3
- Setting: A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
- Sponsor: Jiangsu Alphamab Biopharmaceuticals
- Enrolled: 364

## Notes

- ClinicalTrials.gov record last updated 2026-04-16: recruiting. Enrollment is planned at 364 participants. Primary completion is estimated at 2029-03-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT07533123: https://clinicaltrials.gov/study/NCT07533123

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [JSKN016](https://onco.cc/drugs/jskn016/)
- companies: [Alphamab Oncology](https://onco.cc/companies/alphamab/)

---
JSON: https://onco.cc/api/v1/entities/nct07533123.json